Black Diamond Therapeutics is a next-wave cancer precision medicine company. Black Diamond pioneered the development of selective medicines for patients with genetically defined cancers driven by oncogenes activated by allosteric mutations. Led by an experienced management team Black Diamond has developed a computational and discovery platform with the aim to discover and validate new targets and develop novel approaches to creating highly selective therapeutics. Black Diamond’s first two disclosed programs are targeting groups of EGFR and HER2 allosteric mutants. Black Diamond was founded by David M. Epstein, Ph.D., Elizabeth Buck, Ph.D., and Versant Ventures, and is the first new company to emerge from Versant’s Ridgeline Discovery Engine in Basel, Switzerland. The company is located in Cambridge, Massachusetts and Basel, Switzerland.